Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,101–1,200 of 2,517
A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2
Hsueh, K.-W., Fu, S., Chang, C., Chang, Y., & Lin, C. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.11.005 · Cited by 39
Rodin, S. N., & Rodin, A. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11927 · Cited by 34
Solcia, E., Klersy, C., Mastracci, L., Alberizzi, P., Candusso, M. E., Diegoli, M., Tava, F., Riboni, R., Manca, R., & Luinetti, O. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0813-z · Cited by 35
“This finding on gastric cancer p53 gene mutations fits in with previous results on lung [45, 46], head and neck [47], and colorectal cancers [48]; it is likely to be related to the high concentration of DNA contact and gain of function mutations in exons 7 and 8, with special reference to L3 loop, S-10 band, and loops…”
ResultShi, H., Lambert, J. M. R., Hautefeuille, A., Bykov, V. J. N., Wiman, K. G., Hainaut, P., & de Fromentel, C. C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm266 · Cited by 35
“Mutation of p53gln248 not only has a destabilizing effect but also modifies a residue that makes direct contact with target DNA (25, 26 ).”
BackgroundId4 dependent acetylation restores mutant-p53 transcriptional activity
Knowell, A. E., Patel, D., Morton, D. J., Sharma, P., Glymph, S., & Chaudhary, J. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-161 · Cited by 40
“Both these amino acids (274°F and 273H) are within the conserved region of p53 beta strand S10 whereas 223 L lies in the outer loop [24].”
BackgroundSaxena, A., Shriml, L. M., Dean, M. C., & Ali, I. U. (1999) · Oncogene · doi:10.1038/sj.onc.1202440 · Cited by 38
“Although none of these residues are involved in the direct interaction of p53 with DNA, they may be important for the conformational stability of the p53 protein (Cho et al., 1994).”
BackgroundCao, Y. B., Gao, Q., Wazer, D. E., & Band, V. (1997) · PubMed · Cited by 35
Wang, G. G., Huang, C., Zhao, Y., Ling, C. A. I., Wang, Y., Shi Jin, X. I. U., Jiang, Z. W., Yang, S., Xin Tai, Z. H. A. O., Huang, W., et al. (2000) · Cell Research · doi:10.1038/sj.cr.7290058 · Cited by 35
Bäckvall, H., Strömberg, S., Gustafsson, A. C., Asplund, A., Sivertsson, Å., Lundeberg, J., & Pontén, F. (2004) · Experimental Dermatology · doi:10.1111/j.0906-6705.2004.00211.x · Cited by 36
“3) Of these four mutations, two occurred at codon 248, which represents an amino acid critical for the DNA-binding properties of the p53 protein (24).”
BackgroundAnalysis of p53 Inactivation in a Human T-Cell Leukemia Virus Type 1 Tax Transgenic Mouse Model
Portis, T., Grossman, W. J., Harding, J. C., Hess, J. L., & Ratner, L. (2001) · Journal of Virology · doi:10.1128/jvi.75.5.2185-2193.2001 · Cited by 35
“Studies have shown that most p53 point mutations occur in this region and result in the loss of functional p53 due to destabilization of the three-dimensional protein structure (8).”
BackgroundInfluentialAberrant Protein Folding as the Molecular Basis of Cancer
Scott, M. D., & Frydman, J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-394-1:67 · Cited by 37
Use of mutation spectra analysis software
Rogozin, I. B., Kondrashov, F. A., & Glazko, G. V. (2001) · Human Mutation · doi:10.1002/1098-1004(200102)17:2<151::aid-humu8>3.0.co;2-t · Cited by 35
Vlaycheva, L. A., & Chambers, T. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.12.6172-6184.2002 · Cited by 35
“within loosely structured loops can in some cases significantly affect local folding of proteins and profoundly alter their function (6).”
BackgroundTakeuchi, S., Nakatsu, Y., Nakane, H., Murai, H., Hirota, S., Kitamura, Y., Okuyama, Ä., & Tanaka, K. (1998) · PubMed · doi:10.11501/3143873 · Cited by 36
Maestro, R., Gloghini, A., Doglioni, C., Piccinin, S., Vukosavljevic, T., Gasparotto, D., Carbone, A., & Boiocchi, M. (1997) · Blood · doi:10.1182/blood.v89.7.2523 · Cited by 34
Identification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo
Koga, H., & Deppert, W. (2000) · Oncogene · doi:10.1038/sj.onc.1203745 · Cited by 35
“Ser. Gly245 is located within the L3 loop of the p53 DNA binding domain, which provides major and minor groove contacts with the p53 consensus-DNA element (Cho et al., 1994).”
BackgroundNakano, H., Kohara, M., & Shinohara, K. (2001) · Cell and Tissue Research · doi:10.1007/s004410100438 · Cited by 36
“Codon 176 in human p53 is involved in binding zinc atoms, and its mutation has a dominant-negative effect on normal p53 function ( Cho et al. 1994; Brachman et al. 1996).”
BackgroundMeira, L. B., Reis, A., Cheo, D. L., Nahari, D., Burns, D. K., & Friedberg, E. C. (2001) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(01)00097-5 · Cited by 45
Schneider-Stock, R., Radig, K., Oda, Y., Mellin, W., Ryś, J., Niezabitowski, A., & Roessner, A. (1997) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01240317 · Cited by 35
“At the top, evolutionarily conserved regions ( I I -V) (Cho et al. 1992) are indicated.”
BackgroundInfluentialAn overview of the functions of p53 and drugs acting either on wild- or mutant-type p53
Huang, Y., Jiao, Z., Fu, Y., Hou, Y., Sun, J., Hu, F., Yu, S., Gong, K., Liu, Y., & Zhao, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116121 · Cited by 35
Goh, G., Schmid, R., Guiver, K., Arpornwirat, W., Chitapanarux, I., Ganju, V., Im, S., Kim, S., Dechaphunkul, A., Maneechavakajorn, J., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002136 · Cited by 35
Recognition of Local DNA Structures by p53 Protein
Brázda, V., & Coufal, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020375 · Cited by 38
“The core domain of the p53 protein is mainly responsible for DNA target sequence interactions [77,78], but C-terminal modification is mandatory for effective binding of the full-length protein to the target sequence [79].”
BackgroundThe lncRNA XIST interacts with miR-140/miR-124/iASPP axis to promote pancreatic carcinoma growth
Liang, S., Gong, X., Zhang, G., Huang, G., Lu, Y., & Li, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.22555 · Cited by 35
“Most p53 mutations map to the DNA-binding domain, therefore, they are unable to activate genes up-regulated by wild-type p53, a loss of function that ultimately leads to unchecked cell division [29].”
BackgroundArsic, N., Slatter, T. L., Gadéa, G., Villain, É., Fournet, A., Kazantseva, M., Allemand, F., Sibille, N., Sevéno, M., de Rossi, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25550-2 · Cited by 34
Anti-Transcription Factor RNA Aptamers as Potential Therapeutics
Mondragón, E., & Maher, L. J. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0566 · Cited by 35
Tajima, S., Zhuang, W. Z., Kato, M. V., Okada, K., Ikawa, Y., & Aida, Y. (1998) · Virology · doi:10.1006/viro.1998.9051 · Cited by 36
Zhang, L., Li, Z., Yan, J., Pradhan, P., Corpora, T., Cheney, M. D., Bravo, J., Warren, A. J., Bushweller, J. H., & Speck, N. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303972200 · Cited by 34
Detection of mutant p53 using field-effect transistor biosensor
Han, S. H., Kim, S. K., Park, K., Yi, S. Y., Park, H. J., Lyu, H., Kim, M., & Chung, B. H. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2010.03.006 · Cited by 36
Exposure to ELF magnetic field tuned to Zn inhibits growth of cancer cells
Sarimov, R. M., Markovà, E., Johansson, F., Jenssen, D., & Belyaev, I. Y. (2005) · Bioelectromagnetics · doi:10.1002/bem.20146 · Cited by 34
NOP14 promotes proliferation and metastasis of pancreatic cancer cells
Zhou, B., Wu, Q., Chen, G., Zhang, T., & Zhao, Y.-P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.010 · Cited by 34
“These mutations, including a mutation at residue 273 [40], which is detected in PANC-1 cells [41], can promote the invasive behavior of cells through a gain in function that is independent of the loss of wild-type P53 function [42–44].”
BackgroundSoft Tissue Sarcomas and p53 Mutations
Taubert, H. W., Meye, A., & Würl, P. (1998) · Molecular Medicine · doi:10.1007/bf03401743 · Cited by 40
Ma, B., & Levine, A. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm890 · Cited by 37
“While it was suspected that the AB dimer in the trimeric p53–DNA structure (8) may be caused by crystal packing, it is also possible that the AB dimer has biological significance (11,26,27).”
BackgroundMethodInfluentialQiu, S., Ye, S.-L., Wu, Z.-Q., Tang, Z., & Liu, Y.-K. (1998) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050162 · Cited by 35
“Besides mutation, the function of the p53 gene may also be compromised by the binding of proteins, such as the MDM2 protein (Barak et al. 1993; Cho et al. 1994; Kussie et al. 1996; Momand et al. 1992).”
BackgroundSpectrum of p53 Tumor Suppressor Gene Mutations and Breast Cancer Survival
Lai, H. C., Ma, F., Trapido, E. J., Meng, L., & Lai, S. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000010699.53742.60 · Cited by 34
“, mutations that cause amino acid substitutions) have different effects on the structure of the protein than do silent mutations [35].”
BackgroundWest, A. N., Ribeiro, R. C., Jenkins, J., Galindo, C. R., de Figueiredo, B. C., Kriwacki, R. W., & Zambetti, G. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4580 · Cited by 34
石橋, 玲., Sasaguri, T., Miwa, Y., Kosaka, C., Taba, Y., & Abumiya, T. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.5.938 · Cited by 32
“The DNA-binding domain of p53 also contains several cystein residues that play important roles in binding to DNA (Cho et al., 1994).”
Tolstonog, G. V., Wang, X. R., Shoeman, R. L., et al. (2000) · DNA and Cell Biology · doi:10.1089/10445490050199054 · Cited by 34
High Affinity Insertion/Deletion Lesion Binding by p53
Szak, S. T., & Pietenpol, J. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3904 · Cited by 36
Nichols, K. E., Heath, J. A., Friedman, D., Biegel, J. A., Ganguly, A. A., Mauch, P., & Diller, L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.042 · Cited by 37
Binding geometry of α‐helices that recognize DNA
Suzuki, M., & Gerstein, M. (1995) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340230407 · Cited by 39
The p53/IGF-1 receptor axis in the regulation of programmed cell death
Neuberg, M., Buckbinder, L., Seizinger, B. R., & Kley, N. (1997) · Endocrine · doi:10.1007/bf02778075 · Cited by 34
Coffill, C. R., Lee, A. P., Siau, J. W., Chee, S. M., Joseph, T. L., Tan, Y. S., Madhumalar, A., Tay, B.-H., Brenner, S., Verma, C. S., et al. (2016) · Genes & Development · doi:10.1101/gad.274118.115 · Cited by 35
Xia, Y., Wu, L., Hu, Y., He, Y., Cao, Z. Y., Zhu, X., Yi, X., & Wang, J. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.10.054 · Cited by 34
Николаевна, Н. И., Satriano, C., Curci, A., Margiotta, N., Natile, G., Arena, G., Mendola, D. L., Nicoletti, V. G., & Rizzarelli, E. (2018) · Oncotarget · doi:10.18632/oncotarget.26346 · Cited by 35
“Several other cysteines are located in the regions that bind within the major groove of target DNA [113].”
BackgroundMetabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells
Allende-Vega, N., & Villalba, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42220-y · Cited by 34
FBXL6 degrades phosphorylated p53 to promote tumor growth
Li, Y., Cui, K., Zhang, Q., Lin, X., Lin, X., Tang, Y., Prochownik, E. V., & Li, Y. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00739-6 · Cited by 36
Regulation of transcriptional activation of mdm2 gene by p53 in response to UV radiation.
Saucedo, L. J., Carstens, B. P., Seavey, S. E., Albee, L. D., & Perry, M. E. (1998) · PubMed · Cited by 38
Molecular mechanisms underlying the interaction of protein phosphatase-1c with ASPP proteins
Skene-Arnold, T. D., Luu, H. A., Uhrig, R. G., Wever, V. D., Nimick, M., Maynes, J. T., Fong, A., James, M. N. G., Trinkle‐Mulcahy, L., Moorhead, G. B. G., et al. (2012) · Biochemical Journal · doi:10.1042/bj20120506 · Cited by 34
Harada, K., Bando, T., Yoshida, H., et al. (2001) · Oral Oncology · doi:10.1016/s1368-8375(00)00125-1 · Cited by 33
Structural Basis for p53 Lys120-Acetylation-Dependent DNA-Binding Mode
Vainer, R., Cohen, S., Shahar, A., Zarivach, R., & Arbely, E. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.06.009 · Cited by 33
Al-Saran, N., Subash‐Babu, P., Al-Nouri, D. M., Alfawaz, H., & Alshatwi, A. A. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.08.002 · Cited by 35
Inactivation of Myc-induced p53-dependent apoptosis in human tumors
Arsenian‐Henriksson, M., Selivanova, G., Lindström, M. S., & Wiman, K. G. (2001) · APOPTOSIS · doi:10.1023/a:1009644716727 · Cited by 40
p53 tumor suppressor gene mutations in transformed cutaneous T‐cell lymphoma: A study of 12 cases
Marrogi, A. J., Khan, M. A., Vonderheid, E. C., Wood, G. S., & McBurney, E. I. (1999) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1999.tb01860.x · Cited by 33
Inhibition of Stress-Inducible Kinase Pathways by Tumorigenic Mutant p53
Ohiro, Y., Usheva, A., Kobayashi, S., Duffy, S., Nantz, R., Gius, D. R., & Horikoshi, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.322-334.2003 · Cited by 36
“The p53 mutants 248RW and 273RH have lost an amino acid that is involved in the direct contact with DNA (6) and do not have a detectable conformational change in their DNA-binding domain as judged by their inability to bind HSC70 or PAb240.”
BackgroundMethodIwamoto, K. S. (1999) · Carcinogenesis · doi:10.1093/carcin/20.7.1283 · Cited by 34
“In the tumors, missense mutations were invariably found in the conserved domains of the gene, whereas in the non-tumor tissues, there was less of this clustering (Figure 1). These domains have been shown to be important in the formation of structural elements critical in binding DNA ( 33 ).”
BackgroundCell‐cycle dependent biosynthesis and localization of p53 protein in untransformed human cells
Katsumoto, T., Higaki, K., Ohno, K., & Onodera, K. (1995) · Biology of the Cell · doi:10.1016/0248-4900(96)89426-3 · Cited by 33
New prognostic factors in resectable non-small cell lung cancer.
Smit, E. F., Groen, H. J. M., Splinter, T. A. W., Ebels, T., & Postmus, P. E. (1996) · Thorax · doi:10.1136/thx.51.6.638 · Cited by 36
Dittmann, K., Gueven, N., Mayer, C., Ohneseit, P., Zell, R., Begg, A. C., & Rodemann, H. P. (1998) · Radiation Research · doi:10.2307/3579887 · Cited by 33
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 35
Xu, H. Y., Xue, C., Zhang, R., Chen, Y., Li, F., Shen, Z., Jia, L., & Wu, Z. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.12.107 · Cited by 32
Regulation of transcriptional activators by DNA-binding domain ubiquitination
Landré, V., Revi, B., Gil-Mir, M., Verma, C. S., Hupp, T. R., Gilbert, N., & Ball, K. L. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.42 · Cited by 37
Farkaš, M., Hashimoto, H., Bi, Y., Davuluri, R. V., Resnick‐Silverman, L., Manfredi, J. J., Debler, E., & McMahon, S. B. (2021) · Nature Communications · doi:10.1038/s41467-020-20783-z · Cited by 34
Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
Saleh, A., & Perets, R. (2021) · Cancers · doi:10.3390/cancers13143465 · Cited by 37
“, R248 and R273) influence direct p53 binding to DNA, consequently altering the capacity to trans-activate promoters of its target genes, whereas structural mutations, such as R175, G245, R249 and R282, produce structurally unstable and partially unfolded p53, which perturbates its activity [26,75,76].”
BackgroundXie, T., Zhou, G., Zhao, M., Sano, D., Jasser, S. A., Brennan, R. G., & Myers, J. N. (2013) · The Laryngoscope · doi:10.1002/lary.23846 · Cited by 31
“The second class is termed as conformational mutations, comprising substitution of residues that are involved in conformational changes and including R249S, G245S, R175H, and R282W.29,30 This led us to investigate the effects of the substitution of the proline at position 151 with serine on p53 structure.”
BackgroundOgane, S., Onda, T., Takano, N., Yajima, T., UCHIYAMA, T., & Shibahara, T. (2008) · International Journal of Cancer · doi:10.1002/ijc.24237 · Cited by 32
Discovery of novel tumor suppressor p53 response elements using information theory
Lyakhov, I. G., Krishnamachari, A., & Schneider, T. D. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn189 · Cited by 32
“6 bp) above the logos represent the DNAmajor groove facing the protein, as determined by X-ray crystallography (48) and methylation interference (7).”
BackgroundMolecular dynamics of the full-length p53 monomer
Chillemi, G., Davidovich, P., D’Abramo, M., Mametnabiev, T., Garabadzhiu, A. V., Desideri, A., & Melino, G. (2013) · Cell Cycle · doi:10.4161/cc.26162 · Cited by 31
“2) shows a very good stability of the core domain, mainly characterized by a β sandwich (from β strand S1 to S10) and loop–sheet–helix motifs (composed of loop L1; β strands S2 and S2’; the end of β trand S10 and helix H2, at the C-terminal boundary of the core domain).(90) Helices H2 and H1, in direct interaction wit…”
BackgroundAdaptive Evolution of p53 Thermodynamic Stability
Khoo, K. H., Andreeva, A., & Fersht, A. R. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.013 · Cited by 32
Molecular Dynamic Simulation Insights into the Normal State and Restoration of p53 Function
Fu, T., Min, H., Xu, Y., Chen, J., & Li, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089709 · Cited by 34
Tan, Y. S., Mhoumadi, Y., & Verma, C. S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz009 · Cited by 34
“One of them reveals how the DBD is bound to DNA (Cho et al., 1994 ), while the other shows how the p 53 tetramer is formed from the assembly of a dimer of dimers of the tetra-merization domain (Clore et al., 1994 ).”
BackgroundDuan, W., Ding, H., Subler, M. A., Zhu, W., Zhang, H., Stoner, G. D., Windle, J. J., Otterson, G. A., & Villalona-Calero, M. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205909 · Cited by 33
“…within the sequence-specific DNA-binding domain of the protein, the amino acid residues that are mutated generally fall into one of two classes: (1) those that contact DNA directly, or (2) those that are involved in maintaining the structural integrity of the DNA-binding domain (Cho et al., 1994).”
BackgroundHernández, I., Maddison, L. A., Wei, Y., DeMayo, F. J., Petras, T., Li, B., Gingrich, J. R., Rosen, J. M., & Greenberg, N. M. (2003) · PubMed · Cited by 32
Genes responsible for familial breast cancer.
Cornelisse, C., Cornelis, R., & Devilee, P. (1996) · Pathology, Research and Practice · doi:10.1016/s0344-0338(96)80090-2 · Cited by 25
Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson
Menéndez, D., Inga, A., Jordan, J. J., & Resnick, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210277 · Cited by 40
“For nearly 12 years, there has been only one crystal structure of human p53 bound to DNA (Cho et al., 1994).”
BackgroundFamilial Brain Tumour Syndrome Associated with a p53 Germline Deletion of Codon 236
Lübbe, J., Ammon, K. V., Watanabe, K., Hegi, M. E., & Kleihues, P. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00572.x · Cited by 32
Mulder, F. A. A., Ayed, A., Yang, D., Arrowsmith, C. H., & Kay, L. E. (2000) · Journal of Biomolecular NMR · doi:10.1023/a:1008317825976 · Cited by 32
Matsumoto, M., Furihata, M., Kurabayashi, A., Sasaguri, S., Araki, K., Hayashi, H., & Ohtsuki, Y. (2004) · Oncology · doi:10.1159/000081001 · Cited by 31
Merabet, A., Houlleberghs, H., Maclagan, K., Akanho, E., Bui, T. T. T., Pagano, B., Drake, A. F., Fraternali, F., & Nikolova, P. V. (2010) · Biochemical Journal · doi:10.1042/bj20091888 · Cited by 31
Mapping p53 Mutations in Low-Grade Glioma: A Voxel-Based Neuroimaging Analysis
Wang, Y. Y., Zhang, T., Li, S., Qian, T., Fan, X., Peng, X., Ma, J., Wang, L., & Jiang, T. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4065 · Cited by 33
“properties that enable them to promote proliferation, invasion, metastasis, and cell immortalization.(9,10) Although it has been”
BackgroundKRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients
Gao, W., Jin, J., Yin, J., Land, S. R., Gaither‐Davis, A., Christie, N. A., Luketich, J. D., Siegfried, J. M., & Keohavong, P. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22501 · Cited by 32
Tumours and tumour-like lesions of the liver
Goodman, Z. D., Terracciano, L., & Wee, A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00014-3 · Cited by 34
Hyodo, T., Kuribayashi, N., Fukumoto, C., Komiyama, Y., Shiraishi, R., Kamimura, R., Sawatani, Y., Yaguchi, E., Hasegawa, T., Izumi, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25744-8 · Cited by 44
p53-Induced DNA Bending: The Interplay between p53−DNA and p53−p53 Interactions
Pan, Y., & Nussinov, R. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp800680w · Cited by 35
Genomic landscape of endometrial stromal sarcoma of uterus
Choi, Y. J., Jung, S., Kim, M. S., Baek, I.-P., Rhee, J.-K., Lee, S. H., Hur, S. Y., Kim, T., Chung, Y., & Lee, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.5384 · Cited by 31
“TP53 is the most common tumor suppressor gene that is frequently inactivated in most cancers [27].”
BackgroundThe Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding
Gomes, A. S., Trovão, F., Pinheiro, B., Freire, F., Gomes, S., Oliveira, C., Domingues, L., Romão, M. J., Saraiva, L., & Carvalho, A. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041184 · Cited by 37
“Additionally, residues R175, G245, R249, and R282 are also important for correct folding and DNA-p53 complex stability [4,5].”
BackgroundResidual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
Timofeev, O. N., Klimovich, B., Schneikert, J., Wanzel, M., Pavlakis, E., Noll, J., Mutlu, S., Elmshäuser, S., Nist, A., Mernberger, M., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2019102096 · Cited by 33
“…explanation is that R175 is crucial for the structural integrity of the L2-L3 loop which interacts not only with the minor groove of DNA response elements but also with Bcl-2 family members (Cho et al , 1994; Bullock et al , 2000; Mihara et al , 2003; Tomita et al , 2006; Hagn et al , 2010).”
Identification of p53–46F as a super p53 with an enhanced ability to induce p53‐dependent apoptosis
Nakamura, Y., Futamura, M., Kamino, H., Yoshida, K., Nakamura, Y., & Arakawa, H. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00214.x · Cited by 28
Restoring p53 Tumor Suppressor Activity As an Anticancer Therapeutic Strategy
Martinez, J. D. (2010) · Future Oncology · doi:10.2217/fon.10.132 · Cited by 31
Wenz, H. M., Ramachandra, S., O’Connell, C. D., et al. (1998) · Mutation Research/Mutation Research Genomics · doi:10.1016/s1383-5726(98)00004-1 · Cited by 31
Metallothionein overexpression in human brain tumours
Maier, H., Jones, C. J., Jasani, B., et al. (1997) · Acta Neuropathologica · doi:10.1007/s004010050755 · Cited by 31
“The p53 protein has a DNA binding domain for which a zinc ion is necessary for ensuring a functionally active configuration of the wild-type p53 [ 7 , 8, 16, 33, 34].”
BackgroundLi, Y., Mao, Y., Rosal, R. V., Dinnen, R. D., Williams, A. C., Brandt‐Rauf, P. W., & Fine, R. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.20838 · Cited by 34
Merwin, J. R. (2002) · Carcinogenesis · doi:10.1093/carcin/23.10.1609 · Cited by 31
“The arrangement of nine beta structures in the p53 DNA binding domain ( 9 ) resembles that of NFκB, a protein that has been shown to interact with thioredoxin (28), and for which a NMR structure of a thioredoxin/NFκB peptide complex has been”
BackgroundNovel p53 splice site mutations in three families with Li-Fraumeni syndrome
Verselis, S. J., Rheinwald, J. G., Fraumeni, J. F., & Li, F. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203758 · Cited by 34
“Most alterations cause substitutions of evolutionarily conserved amino acid residues that make direct contact with DNA, or maintain the conformational structure of the protein's DNA binding surface (Soussi et al., 1990; Cho et al., 1994).”
BackgroundFulci, G., Ishii, N., Maurici, D., Gernert, K. M., Hainaut, P. L., Kaur, B., & Meir, E. G. V. (2002) · PubMed · Cited by 31
CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties.
Conseiller, E., Debüssche, L., Landais, D., Venot, C., Maratrat, M., Sierra, V., Tocqué, B., & Bracco, L. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1140 · Cited by 33
Phillips, E. N., Xia, F., Kelsey, K. T., et al. (1995) · Radiation Research · doi:10.2307/3579211 · Cited by 31
Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family
Evans, S. C., Mims, B. H., McMasters, K. M., Foster, C. J., deAndrade, M., Amos, C. I., Strong, L. C., & Lozano, G. (1998) · Human Genetics · doi:10.1007/s004390050761 · Cited by 31
“Most of these were missense mutations in the conserved regions of the p53 DNA-binding domain (Cho et al. 1994).”
BackgroundWitte, J. H. D., Foekens, J. A., Lennerstrand, J. A., et al. (1996) · Radboud Repository (Radboud University) · doi:10.1002/(sici)1097-0215(19960422)69:2<125::aid-ijc10>3.0.co;2-8 · Cited by 31
Overexpression of p53 protein in human tumors
Inoue, K., Kurabayashi, A., Shuin, T., Ohtsuki, Y., & Furihata, M. (2012) · Medical Molecular Morphology · doi:10.1007/s00795-012-0575-6 · Cited by 35
“This region is a core DNA-binding domain (DBD; residues 93–292) of p53 and the target of mutations frequently found in human tumors.(24) More than 95% of the”
BackgroundLepre, M. G., Omar, S. I., Grasso, G., Morbiducci, U., Deriu, M. A., & Tuszyński, J. A. (2017) · Molecules · doi:10.3390/molecules22081358 · Cited by 31
“Furthermore, p53 binds to DNA as a tetramer composed of four identical subunits [27], consisting of a dimer of dimers located symmetrically on the consensus site [8,9].”
BackgroundInfluential
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.